Two EU biotechs, the privately held Crescendo Biologics Ltd. and the publicly quoted BerGenBio ASA, have taken different approaches to moving potential products into early clinical studies, the first with the support of a UK charity, and the second with the support of international investors.
Crescendo, BerGenBio Find Support For Cancer Studies
EU Biotechs Get Support From Charities And Investors
European biotech companies are finding diverse ways of finding support and financing to propel their potential first-in-class therapies into clinical studies, including sponsorship by patient charities as well as private placements.
More from Immuno-oncology
• By
With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.
• By
Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.
• By
Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.
• By
Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.
More from Anticancer
• By
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
• By
The drug maker presented data from two cohorts of a pivotal Phase IIb study in NMIBC. Cost and ease of administration offer the potential to benefit the drug commercially.
• By
With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.